Infliximab and adalimumab, etanercept and ustekinumab are of equal therapeutic value in the treatment of adults suffering from mild to moderately severe plaque psoriasis who do not respond sufficiently to – or do not tolerate – other systemic therapies, including ciclosporin, methotrexate and PUVA.

This report is a summary of recommendations by the National Health Care Institute. The original text is in Dutch.